Merck is building a $1B biotech center in Wilmington, deepening its local footprint and teaming with Horsham-based MRA Group at Chestnut Run.
Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center of excellence” in Wilmington, writes John George and Paul Schwedelson for Philadelphia Business Journal.
The new facility, dubbed Merck Wilmington Biotech, will anchor the Chestnut Run Innovation & Science Park, a sprawling campus developed by Horsham-based MRA Group. The site will house manufacturing, lab, and warehouse space and serve as the primary U.S. production center for Keytruda. The blockbuster cancer drug generated nearly $30 billion in sales last year…